Cabio Biotech holds a total of 168.31 Million outstanding shares. Cabio Biotech Wuhan retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Cabio Biotech in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Cabio Biotech, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Cabio
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabio Biotech Wuhan. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Cabio Stock Ownership Analysis
About 51.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 1.97. In the past many companies with similar price-to-book ratios have beat the market. Cabio Biotech Wuhan last dividend was issued on the 26th of June 2024. The entity had 1.4:1 split on the 18th of July 2023. For more info on Cabio Biotech Wuhan please contact the company at 86 27 6784 5351 or go to https://www.cabio.cn.
Cabio Biotech Outstanding Bonds
Cabio Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cabio Biotech Wuhan uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cabio bonds can be classified according to their maturity, which is the date when Cabio Biotech Wuhan has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Cabio Biotech financial ratios help investors to determine whether Cabio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cabio with respect to the benefits of owning Cabio Biotech security.